
Healthcare insurance company Molina Healthcare (NYSE: MOH) met Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 3.1% year on year to $10.8 billion. On the other hand, the company’s full-year revenue guidance of $42 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $2.35 per share was 21.4% above analysts’ consensus estimates.
Is now the time to buy Molina Healthcare? Find out by accessing our full research report, it’s free.
Molina Healthcare (MOH) Q1 CY2026 Highlights:
- Revenue: $10.8 billion vs analyst estimates of $10.83 billion (3.1% year-on-year decline, in line)
- Adjusted EPS: $2.35 vs analyst estimates of $1.94 (21.4% beat)
- The company dropped its revenue guidance for the full year to $42 billion at the midpoint from $44.5 billion, a 5.6% decrease
- Management reiterated its full-year Adjusted EPS guidance of $5 at the midpoint
- Operating Margin: 0.8%, down from 3.9% in the same quarter last year
- Free Cash Flow Margin: 9.8%, up from 1.5% in the same quarter last year
- Customers: 5.03 million, down from 5.49 million in the previous quarter
- Market Capitalization: $7.87 billion
Company Overview
Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE: MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, Molina Healthcare’s 16.2% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Molina Healthcare’s annualized revenue growth of 12.1% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. 
We can better understand the company’s revenue dynamics by analyzing its number of customers, which reached 5.03 million in the latest quarter. Over the last two years, Molina Healthcare’s customer base averaged 1.9% year-on-year declines. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company’s products and services. 
This quarter, Molina Healthcare reported a rather uninspiring 3.1% year-on-year revenue decline to $10.8 billion of revenue, in line with Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Molina Healthcare was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 3.8% was weak for a healthcare business.
Looking at the trend in its profitability, Molina Healthcare’s adjusted operating margin decreased by 2.9 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 3.6 percentage points. We still like Molina Healthcare but would like to see some improvement in the future.

This quarter, Molina Healthcare generated an adjusted operating margin profit margin of 1.1%, down 3.2 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Molina Healthcare, its EPS declined by 15.3% annually over the last five years while its revenue grew by 16.2%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

We can take a deeper look into Molina Healthcare’s earnings to better understand the drivers of its performance. As we mentioned earlier, Molina Healthcare’s adjusted operating margin declined by 2.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q1, Molina Healthcare reported adjusted EPS of $2.35, down from $6.08 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Molina Healthcare’s full-year EPS of $6.92 to shrink by 18.3%.
Key Takeaways from Molina Healthcare’s Q1 Results
It was good to see Molina Healthcare beat analysts’ EPS expectations this quarter. On the other hand, its full-year revenue guidance missed and its full-year EPS guidance fell slightly short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded up 2.1% to $156.25 immediately after reporting.
So should you invest in Molina Healthcare right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).

